Breast cancer is the most frequent cancer in women and the second most frequent cause of cancer death among women within the United States.
Conclusions: Performing Oncotype DX on low-grade invasive carcinomas is unlikely to provide additional useful information beyond Magee equation RS, and eliminating Oncotype DX from these cases could lead to substantial cost savings.
Breast cancer is the most frequent cancer in women and the second most frequent cause of cancer death among women within the United States. 1 Breast cancer is a morphologic and genetic heterogeneous entity 2, 3 and has been classified into clinically and biologically meaningful groups based on their histopathologic features, defined by histologic grade and type. Histologic grade and type provide complementary information about the features of breast cancers. [4] [5] [6] Several specific histologic types of breast carcinoma, including invasive tubular carcinoma (ITC), invasive mucinous carcinoma (IMC), and classical invasive lobular carcinoma (CILC), are low grade and associated with a good prognosis. [5] [6] [7] [8] [9] Multiple molecular assays have been developed to assess the genomic profile, determine patient risk, and predict prognosis in breast cancer. 10, 11 Oncotype DX (Genomic Upon completion of this activity you will be able to:
• summarize the limitations of Oncotype DX recurrence scores (RSs) for breast carcinoma.
• list factors in low-grade invasive breast carcinomas that may contribute to an artificially increased Oncotype DX RS.
• select patients who are unlikely to benefit from Oncotype DX testing.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Exam is located at www.ascp.org/ajcpcme. 
© American Society for Clinical Pathology

Materials and Methods
Patients and Data Retrieval
Study Design
Three Magee equations using different combinations of standard histopathologic variables (Nottingham score, ER, PR, HER2, Ki-67, and tumor size) were published to predict Oncotype DX RS and are available at the website of the University of Pittsburgh Medical Center MageeWomens Hospital pathology department (http://path.upmc. edu/onlineTools/mageeequations.html). Since many cases in our study cohort did not have Ki-67 results, we used Magee equation 2 (RS = 18.8042 + Nottingham score * 2.34123 + ER H-score * (-0.03749) + PR H-score * (-0.03065) + (0 for HER2 negative, 1.82921 for equivocal, 11.51378 for positive) + tumor size * 0.04267), which does not require a Ki-67 value. The H-score for ER or PR used in the Magee equation is calculated by multiplying staining percentage (0-100) by intensity (1-3) to obtain a value from 0 to 300. We estimated the H-score by multiplying the predominant intensity grade (0-3) by the total stained percentage of cells (0-100).
Statistical Analysis
All clinicopathologic data were summarized using percentages and descriptive statistics (mean, range, frequencies). The modified Magee equation RS was compared with the paired Oncotype DX RS to assess correlation (Pearson correlation) and concordance. The t test was used to compare the continuous values among different groups. For all results, a P value of less than .05 was considered significant. All data analyses were performed using the statistical Analysis ToolPak (Microsoft Excel Office 2010 version; Microsoft, Redmond, WA).
Results
Correlation and Concordance Between Modified Magee Equation RS and Oncotype DX RS
The clinicopathologic features of all patients are summarized in ❚Table 1❚ and separated into three groups with low (<18), intermediate (18- 1 CILC ❚Image 1❚. Oncotype DX RSs for these two cases were 32 and 36, respectively, but modified Magee equation RSs were 20.3 and 20.0, respectively. Tissue blocks sent for Oncotype DX from both cases were reviewed, and both blocks showed a large biopsy cavity with prominent lymphocytic infiltrate around the tumor (Image 1). The first patient did not undergo chemotherapy, and the second patient had four cycles of chemotherapy with the combination of doxorubicin (Adriamycin) and cyclophosphamide. Both patients had been followed up for over 5 years, with no recurrent disease ( Table 4) .
Discussion
This is one of a few studies addressing Oncotype DX's utility and is the first study, to our knowledge, to compare Oncotype DX RS with the modified Magee equation RS in low-risk subtypes of breast cancer. Our recent study demonstrated an excellent concordance between Oncotype DX RS and the modified Magee equation RS with an overall agreement of 66.4% in 438 invasive breast carcinomas, which also included 92 ILCs, 11 IMCs, and three ITCs. 19 In the current study, we focused on these three specific low-grade histologic types with an expanded cohort (105 CILCs, 41 ITCs, and 17 IMCs (H&E, ×25) . B, Case 1 with low nuclear grade of invasive lobular carcinoma with chronic inflammation (H&E, ×100). C, Case 2 showing invasive lobular carcinoma close to biopsy site (H&E, ×25). D, Case 2 with low nuclear grade of invasive lobular carcinoma with chronic inflammation (H&E, ×100).
